Silo Pharma, Inc., a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems,  announced that it has engaged Veloxity Labs, LLC for bioanalysis supporting the ongoing investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetics study of its lead asset, SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD).

“We look forward to working with Veloxity Labs for GLP sample analysis in our current safety study of SPC-15,” said Eric Weisblum, CEO of Silo. “We expect Veloxity to provide fast turnaround times and precise, high-quality data, and we believe their team will play an important role in delivering preclinical data we need to open an IND for SPC-15.”

Silo expects to begin the FDA IND process for SPC-15 in 2025. Upon approval of the IND, Silo will proceed to a first-in-human Phase 1 clinical trial.